Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience Prices Upsized $300M Public Offering

NEW YORK – Twist Bioscience announced on Wednesday after the close of the market the pricing of an upsized $300 million public offering of common stock at $110 per share.

The South San Francisco, California-based firm will offer approximately 2.8 million shares, including 75,000 shares to be sold by certain shareholders.

Twist has granted the underwriters a 30-day option to purchase up to an additional 409,090 shares at the public offering price, less the underwriting discount and commissions.

Twist initially said it planned to offer $250 million worth of shares. It expects the offering to close on or about Dec. 7, 2020, subject to customary closing conditions. Twist will not receive any proceeds from the sale of shares by the selling stockholders.

This is the third stock offering this year for the company after it raised more than $230 million in public offerings in February and June.

In morning trading on the Nasdaq, shares of Twist were up 4 percent at $119.93.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.